Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $375.00 Price Target at Chardan Capital

Key Points

• Chardan Capital cut Alnylam’s price target to $375 from $425 but maintained a “buy” rating, implying substantial upside from the stock’s prior close.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $325.39, despite several recent target reductions.
• Alnylam reported quarterly revenue of $1.46 billion, up 16.7% year over year, and significantly beat EPS estimates; however, concerns over slower Amvuttra demand and uncertainty surrounding its TTR franchise have weighed on the shares.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective cut by research analysts at Chardan Capital from $425.00 to $375.00 in a report issued on Friday. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Chardan Capital's target price points to a potential upside of 127.42% from the stock's previous close.

Several other brokerages also recently weighed in on ALNY. Jefferies Financial Group increased their price target on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a "hold" rating in a report on Tuesday, September 8th. Citigroup dropped their price target on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a "buy" rating on the stock in a research note on Wednesday, October 14th. TD Cowen cut their price target on shares of Alnylam Pharmaceuticals from $482.00 to $354.00 and set a "buy" rating for the company in a report on Friday. HC Wainwright reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday. Finally, Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an "equal weight" rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $325.39.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $9.11 during trading on Friday, hitting $164.89. The company had a trading volume of 6,058,994 shares, compared to its average volume of 1,507,400. The firm has a market capitalization of $22.06 billion, a price-to-earnings ratio of 30.65 and a beta of 0.28. The stock has a fifty day simple moving average of $237.78 and a two-hundred day simple moving average of $287.22. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a fifty-two week low of $163.30 and a fifty-two week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share for the quarter, beating analysts' consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period last year, the company posted $2.90 EPS. Alnylam Pharmaceuticals's quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts expect that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the firm's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president owned 12,807 shares of the company's stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Toth Financial Advisory Corp purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at approximately $25,000. Burkett Financial Services LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $37,000. CoreCap Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 744.4% in the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 134 shares in the last quarter. Keating Financial Advisory Services Inc. bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $42,000. Finally, Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $48,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up 16.7% year over year and above expectations. Adjusted earnings of $16.26 per share also exceeded consensus by a wide margin, although much of the earnings surprise was attributed to a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue beat
• Positive Sentiment: The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion to $4.5 billion in 2026 TTR-related sales. Alnylam also continued advancing its RNAi pipeline, including the nucresiran program. Alnylam TTR sales outlook
• Neutral Sentiment: Several analysts lowered their price targets following the results, but most still see potential upside. TD Cowen, Goldman Sachs, RBC and Needham retained positive ratings, while Morgan Stanley and Wells Fargo kept equal-weight ratings. Analyst price-target changes
• Negative Sentiment: Investors were concerned about slower U.S. Amvuttra patient starts and decelerating growth in Amvuttra and Onpattro sales. Those trends raised questions about demand and the durability of Alnylam’s core commercial growth. Demand growth concerns
• Negative Sentiment: Management acknowledged that execution needs to improve as uncertainty grows around the TTR franchise. The expansion of the TRITON-CM heart-disease trial to roughly 2,250 patients reinforced concerns about development costs, timing and the path toward a potential launch around 2030. Uncertainty around Alnylam’s TTR franchise
• Negative Sentiment: Analyst sentiment became more cautious: Bernstein downgraded ALNY to market perform, Stifel cut the stock to hold, and multiple firms reduced price targets. A disclosed law-firm investigation related to an earlier stock-price decline adds another potential overhang. Stifel downgrade

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.